×
Pulmatrix Net Current Debt 2014-2025 | PULM
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Pulmatrix net current debt from 2014 to 2025. Net current debt can be defined as the net amount of debt repaid and issued with short-term maturities.
View More
Pulmatrix Net Current Debt 2014-2025 | PULM
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Pulmatrix net current debt from 2014 to 2025. Net current debt can be defined as the net amount of debt repaid and issued with short-term maturities.
Related Stocks
Company Name
Market
Cap
AstraZeneca (AZN)
$228.1B
Amgen (AMGN)
$155.2B
Gilead Sciences (GILD)
$148.2B
Vertex Pharmaceuticals (VRTX)
$94B
Bristol Myers Squibb (BMY)
$93.5B
CSL (CSLLY)
$82.7B
GSK (GSK)
$77.1B
Regeneron Pharmaceuticals (REGN)
$59.7B
Alnylam Pharmaceuticals (ALNY)
$57.5B
Argenex SE (ARGX)
$40.5B
BioNTech SE (BNTX)
$26.8B
Insmed (INSM)
$23.2B
Royalty Pharma (RPRX)
$21.1B
Biogen (BIIB)
$19.2B
Incyte (INCY)
$15.3B
Illumina (ILMN)
$14.5B
Genmab (GNMSF)
$14.3B
Genmab (GMAB)
$13.7B
Ascendis Pharma (ASND)
$11.7B
BioMarin Pharmaceutical (BMRN)
$11B
QIAGEN (QGEN)
$10.7B
Swedish Orphan Biovitrum (BIOVF)
$10.6B
Moderna (MRNA)
$10.2B
Exelixis (EXEL)
$10.2B
Verona Pharma American Depositary Share (VRNA)
$9B
Blueprint Medicines (BPMC)
$8.3B
Bio-Techne Corp (TECH)
$7.9B
Roivant Sciences (ROIV)
$7.8B
Exact Sciences (EXAS)
$7.8B
Halozyme Therapeutics (HALO)
$7.8B